Cytomx Therapeutics, Inc. · NASDAQ:CTMX
Cytomx Therapeutics — ESMO 2018
30 slides from Cytomx Therapeutics's conference presentation, Oct 22, 2018
Slide 1: PROCLAIM CX-072 ESMO 2018 Clinical Presentations
PROCLAIM CX-072 ESMO 2018 Clinical Presentations October 22, 2018 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding
Slide 3: Introduction
Introduction Sean McCarthy, D. Phil. President and Chief Executive Officer
Slide 4: Reinventing Therapeutic Antibodies
Reinventing Therapeutic Antibodies Imaging of Active Protease1 Normal Colon Primary Colon Cancer Metastatic Colon Cancer 1. Matriptase: LeBeau, et al., PNAS 2012 Probody™ Therapeutics: Activated in Tumor Tissue Proteases: Active in Tumor Tissue Antibodies are a very successful therapeutic class in m
Slide 5: Deep and Differentiated Probody Pipeline
Deep and Differentiated Probody Pipeline Immunotherapies Probody Drug Conjugates Pb T Cell Engaging Bispecifics Multiple Programs PRODUCT CANDIDATE LEAD OPTIMIZATION IND-ENABLING PHASE 1/2 COMMERCIAL RIGHTS CX-072 CX-2009 BMS-986249 CX-2029 CX-188 Probody Drug Conjugate Pb T Cell Bispecific Addition
Slide 6: CX-072 as a Potentially Differentiated Centerpiece of Combination Cancer Therapy
CX-072 as a Potentially Differentiated Centerpiece of Combination Cancer Therapy CX-072 PD-L1 PROBODY THERAPEUTIC Checkpoint Inhibitors E.g. Yervoy® Probody Tx PDCs Pb-TCBs Other Cancer Immuno- therapies Kinase Inhibitors E.g. Zelboraf® ADCs Validated target Well-established efficacy & safety for cl
Slide 7: PROCLAIM-CX-072 Trial Design
PROCLAIM-CX-072 Design: Exploratory Studies 2018-2019, Expansion Studies 2019-2020 Initiation: Q3 2017 Inclusion: Unselected cancer types Data Presentations: ESMO 2018 A1: DOSE ESCALATION Initiation: January 2017 Inclusion: PD naïve, unselected cancer types Data Presentations: ESMO 2018 A2: MANDATOR
Slide 8: CX-072 Clinical Data Presentations 2018 ESMO Annual Meeting
CX-072 Clinical Data Presentations 2018 ESMO Annual Meeting Poster #435 Preliminary Results of the First-In-Human, Dose-Finding PROCLAIM-072 Trial of PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients with Advanced Solid Tumors Presenter:Valentina Boni, M.D., Ph.D., TART Madrid CIOCC Hospit
Slide 9: Summary of CX-072 Updates Provided at ESMO
Summary of CX-072 Updates Provided at ESMO CX-072 Monotherapy (PROCLAIM-CX-072 Part A1, A2) Part A1 follow up largely complete (22 patients; 0.03 – 30mg/kg) Well tolerated 3 PRs, including 1 confirmed PR TNBC (on treatment for 48 weeks as of data cutoff) Snapshot of Part A2; mandatory biopsy arm (0.
Slide 10: CX-072 Anti PD-L1 Probody Therapeutic: Monotherapy and Ipilimumab Combination Clinical Results
CX-072 Anti PD-L1 Probody Therapeutic: Monotherapy and Ipilimumab Combination Clinical Results Presented at 2018 ESMO Rachel Humphrey, M.D. Chief Medical Officer
Slide 11: Monotherapy Dose Escalation Design
PROCLAIM-CX-072 Monotherapy Dose Escalation Design Patients heavily pre-treated and PD-L1 positive a CX-072 monotherapy was administered intravenously every 14 days. One patient each was enrolled in the 0.03, 0.1, and 0.3 mg/kg dosing cohorts, and subsequent dose levels follow a 3+3 design, which is
Slide 12: Monotherapy Dose Escalation: CX-072 Well Tolerated in Heavily Pre-treated Patients
PROCLAIM-CX-072 Monotherapy Dose Escalation: CX-072 Well Tolerated in Heavily Pre-treated Patients 46 evaluable patients MTD not reached Most treatment-related AEs (TRAEs) were Grade 1/2 5 patients (11%) experienced a Grade 3-4 TRAE 3 patients (7%) experienced an irAE AE, adverse event; irAE, immune
Slide 13: Monotherapy Dose Escalation: Encouraging Anti-tumor Activity Observed
PROCLAIM-CX-072 Monotherapy Dose Escalation: Encouraging Anti-tumor Activity Observed in Heavily Pre-Treated Patients 38 evaluable patients with no available PD-1, PD-L1 inhibitors for their disease 3 PR: TNBC (confirmed PR 10 mg/kg); thymoma (unconfirmed PR (uPR) 3 mg/kg); cervical (uPR 10 mg/kg) 1
Slide 14: Monotherapy Dose Escalation: Waterfall Plot
PROCLAIM-CX-072 Monotherapy Dose Escalation: Waterfall Plot Among patients with measurable target lesions at baseline (n = 37), target lesions decreased from baseline in 14 (38%) patients and at dose levels ≥3 mg/kg in 10/17 (59%) patients per RECIST v1.1. CCC, cholangiocellular carcinoma; ER+ BC, b
Slide 15: Monotherapy Dose Escalation: Spider Plot
PROCLAIM-CX-072 Monotherapy Dose Escalation: Spider Plot TNBC
Slide 16: Initial CX-072 Case Study: Confirmed Partial Response in Triple Negative Breast Cancer Patient
Reduction of Tumor Burden Patient Profile 39 years old, Microsatellite Stable, TMB low, PD-L1 negative Initial CX-072 Case Study: Confirmed Partial Response in Triple Negative Breast Cancer Patient Three prior lines of therapy Post mastectomy and left reconstruction with radiotherapy Received CX-072
Slide 17: Dose Escalation: Single Dose PK Supports Platform MoA
PROCLAIM-CX-072 Dose Escalation: Single Dose PK Supports Platform MoA Single-dose CX-072 PK data suggests that CX-072 circulates predominantly as the intact prodrug species Clearance is minimally influenced by target mediated drug disposition Figure B is reprinted by permission from Springer Nature.
Slide 18: PROCLAIM-CX-072 Dose Escalation: Key Takeaways
CX-072 is Well-Tolerated MTD not reached in escalation through 30 mg/kg cohort Probody therapeutic well tolerated No differences in toxicity observed across all dose cohorts 5/46 (11%) patients experiencing a Grade 3/4 TRAE 3/46 (7%) patients experienced a Grade 3/4 irAE PROCLAIM-CX-072 Dose Escalat
Slide 19: Full Potential for Combination Immunotherapy is Limited by Immune-Related Toxicities
Full Potential for Combination Immunotherapy is Limited by Immune-Related Toxicities 1. Larkin et al., NEJM, July 2015. Nivo + Ipi toxicity 64 patients with advanced or unresectable melanoma Nivolumab + Ipilimumab 38 (59%) Grade 3/4 irAE 46 (72%) required steroids 91% irAE leading to emergency depar
Slide 20: Ipilimumab Combination Safety Summary
PROCLAIM-CX-072 Ipilimumab Combination Safety Summary: Initial Observations Supported with Further Follow Up 20 evaluable patients Weakly immunogenic tumors MTD not reached irAEs occurred in 3 of 20 patients (15%); Grade 3 irAEs occurred in 2 patients (10%) Most treatment-related AEs (TRAEs) were Gr
Slide 21: Ipilimumab Combination: irAE Safety Summary
PROCLAIM-CX-072 Ipilimumab Combination: irAE Safety Summary irAE, immune-related adverse event. a Dyspnea and pneumonitis occurred in the same patient. irAEs were defined as treatment-related AEs that were on a predefined list of >300 preferred terms, and that required treatment with systemic steroi
Slide 22: Ipilimumab Combination Dose Escalation: Initial Anti-tumor Activity Observed
PROCLAIM-CX-072 Ipilimumab Combination Dose Escalation: Initial Encouraging Anti-tumor Activity Observed in Ongoing Study Best Tumor Response in Evaluable Patients a per RECIST v1.1, n (%) 14 evaluable patients with no available PD-1, PD-L1 inhibitors for their disease 1 confirmed complete response
Slide 23: Ipilimumab Combination: Waterfall Plot
PROCLAIM-CX-072 Ipilimumab Combination: Waterfall Plot ER+ BC, breast (ER+) carcinoma; HNSCC, head and neck squamous cell carcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; TNBC, triple-negative breast cancer; RECIST, Response Evaluation Criteria in Solid Tumors * Patient is stil
Slide 24: Ipilimumab Combination: Spider Plot
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; RECIST, Response Evaluation Criteria in Solid Tumors * Patient is still receiving treatment. One patient (glioblastoma) had increases up to 392.6%, which have been omitted from this plot (with annotated values)
Slide 25: PROCLAIM-CX-072 Ipilimumab Combination: Key Takeaways
Well-Tolerated Ipilimumab (3 mg/kg) combination: favorable safety profile 20% Grade 3/4 rate trending below the level reported for other PD-1 pathway inhibitors in combination with ipilimumab1 15% overall irAE rate No new safety signals beyond those expected for other anti-PD-1 pathway inhibitors or
Slide 26: Summary
Summary Sean McCarthy, D. Phil. President and Chief Executive Officer
Slide 27: Next Steps: Clinical Proof of Concept Supports Program Expansion
PROCLAIM-CX-072 Next Steps: Clinical Proof of Concept Supports Program Expansion D: 8 UNDISCLOSED TUMOR TYPES Initiation: 2Q 2018 Enrollment ongoing EXPANSION Initiation: 2019 SELECTED CANCER TYPES Trial not initiated CX-072 MONOTHERAPY CX-072 COMBINATION WITH IPILUMIMAB Potential to advance one or
Slide 28: November Presentations Provide Clinical Program Updates
November Presentations Provide Clinical Program Updates Society for Immunotherapy of Cancer Annual Meeting November 9-11, 2018 – Washington, DC Poster: “Preliminary Evidence of Intratumoral Activation and Immunomodulatory Effect of CX-072, a Probody Therapeutic Antibody Prodrug Targeting PD-L1, in a
Slide 29: Thank you
rT si. e, VTL ™ Z \ 1O JN } { a ¥ THERAPEUTICS a \ Thank you
Slide 30: Question and Answer Session
bs THERAPEUTICS Question and Answer Session